Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Apr;12(2):135-6.
doi: 10.1007/s10194-011-0333-5. Epub 2011 Mar 27.

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine

Michael Bjørn Russell
Editorial

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine

Michael Bjørn Russell. J Headache Pain. 2011 Apr.
No abstract available

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Grande RB, Aaseth K, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of primary chronic headache in a population-based sample of 30–44 year old persons. The Akershus Study of Chronic Headache. Neuroepidemiology. 2008;30:76–83. doi: 10.1159/000116244. - DOI - PubMed
    1. Aaseth K, Grande RB, Gulbrandsen P, Lundqvist P, Russell MB. Epidemiology of chronic secondary headaches. A population based study of 30,000 persons. Cephalalgia. 2008;28:705–713. doi: 10.1111/j.1468-2982.2008.01577.x. - DOI - PubMed
    1. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. doi: 10.1177/0333102410364676. - DOI - PubMed
    1. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, on behalf of PREEMPT 2 Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. doi: 10.1177/0333102410364677. - DOI - PubMed
    1. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of the PREEMPT Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936. doi: 10.1111/j.1526-4610.2010.01678.x. - DOI - PubMed

Publication types

MeSH terms

Substances